Insider buying last 90 days
$148Kin 1 open-market purchase
| Filed | Insider | Type | Value |
|---|---|---|---|
| Nov 13 | Hayden Michael R director | Purchase | $148K |
From Form 4 filings, dated to when each was filed.
Nov 13 close
Ionis shares fell sharply this week after third-quarter results. The company reported sales up 54.78% to $243 million, beating estimates, and narrowed its adjusted loss per share to $(0.40), ahead of consensus. Despite these beats, Ionis lowered its 2026 TRYNGOLZA revenue guidance to approximately $50 million, down from a prior target of $100 million to $110 million, citing slower-than-expected uptake and competitive pressure in severe hypertriglyceridemia. DAWNZERA's third-quarter product sales rose 40% to $37 million. The company also pushed back its target for sustained positive cash flow by a year, and at least one law firm has announced an investigation notice tied to the guidance cut.
IONS closed at $31.00, down 21.4% on the day and now at a 52-week low, with the 52-week range spanning $27.75 to $86.74. The stock trades below both its 50-day average of $46.20 and its 200-day average of $65.58, with the shorter average itself below the longer one, reflecting a one-month decline of 31.5% and a six-month decline of 58.9%. The GekkoIndex reads 78.5, placing the stock in the Buying zone. Price sits 48.5% below the Gekko Fair Value of $60.15.
No confirmed earnings date appears on the calendar following the 29 July 2026 report, where Ionis beat EPS estimates and the stock moved -3.7% on the news. Over the last 30 days, 2 unusual options signals were recorded, with call premium of $333,630 against put premium of $250,635. One trailblazer holder is noted. Seasonality over the next 20 trading days has averaged -2.3% across 5 years, rising in 2 of them, a pattern worth noting given current volatility, with a typical 20-day move of 6.2%.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Ionis Pharmaceuticals scores 4 supportive, 0 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive0 mixed2 headwinds
Below 50 and 200-day
Close $29.06 is below the 50-day ($43.66) and 200-day ($64.50) averages, and the 50-day is below the 200-day.
See the chart76.4, Buying
Reading 76.4 is in the Buying zone.
See the GekkoIndex44.5% below
Price is 44.5% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 90 days: 1 open-market insider purchase. Last 30 days: 2 unusual options signals.
See smart moneyReports in 101 days
Next report Feb 24, 2027, 101 days away — outside a typical 20-trading-day hold.
See earnings−2.3% on average
From this point in the calendar, the next 20 trading days averaged −2.3% over 5 years, rising in 1 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Ionis Pharmaceuticals closed at $29.06 on Nov 13, 2026, −60.0% over the past year, inside a 52-week range of $27.25 to $86.74.
Use the left and right arrow keys to read daily values.
Put IONS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Ionis Pharmaceuticals works on medicines built around RNA-targeting technology, focused on treating rare and genetic conditions. Its marketed products include a therapy for spinal muscular atrophy, an injectable for a nerve condition linked to hereditary transthyretin-mediated amyloidosis, and a treatment for two rare lipid disorders. The company has become associated with this RNA-based approach to drug design.
Beyond its approved medicines, Ionis runs a pipeline of candidates in late-stage trials, covering conditions such as TTR amyloidosis, severe high triglycerides, hereditary angioedema, ALS, cardiovascular disease tied to elevated lipoprotein(a), and a genetic form of ALS treated through inhibiting a specific protein's production. It also researches treatments in metabolic, infectious, renal, ophthalmic and oncology areas. Much of its work is carried out through partnerships, including a strategic collaboration with Biogen, along with licensing and collaboration agreements with AstraZeneca, Bayer, GlaxoSmithKline, Novartis, Roche, Janssen Biotech and Flamingo Therapeutics.
Ionis Pharmaceuticals was founded in 1989 and is headquartered in Carlsbad, California. Its shares are listed on the NASDAQ under the ticker IONS.
Ionis Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 76.4, in the Buying zone, up 6.9 points over five sessions.
Up 6.9 points over five sessions, from the Accumulation zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 54 | +0.3% | +1.6% | ||
| Accumulation | 259 | −0.7% | −1.2% | ||
| Neutral | 346 | +0.6% | +1.1% | ||
| Distribution | 38 | −0.5% | +1.9% | ||
| Selling | 5 | Too few readings yet | |||
Average IONS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +2.9% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
Ionis Pharmaceuticals trades 44.5% below Gekko Fair Value of $52.36, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Ionis Pharmaceuticals shares are worth, recalculated every trading day.
$52.36
Gekko Fair Value, Nov 14, 2026
44.5% Undervalued
At the end of Aug 2026 the price was 23.7% below the estimate.
Insiders filed 1 open-market purchase in Ionis Pharmaceuticals worth $148K, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
$148Kin 1 open-market purchase
| Filed | Insider | Type | Value |
|---|---|---|---|
| Nov 13 | Hayden Michael R director | Purchase | $148K |
From Form 4 filings, dated to when each was filed.
No trades in IONS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Ionis Pharmaceuticals has been buying back its own shares.
From company filings.
2signals, 57% of the flagged premium in calls.
Latest: Bearish flow on Oct 30, $251K in unusual premium.
0of the funds Gekko tracks hold IONS.
Ionis Pharmaceuticals reports on Feb 24, 2027 (101 days away), and beat the EPS estimate in 7 of its last 8 reports.
Feb 24, 2027
101 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 9, 2026 | −$0.66 est −$1.23 | $243.0M est $178.2M | −28.5% |
| Jul 29, 2026 | −$0.70 est −$1.09 | $268.0M est $189.1M | −3.7% |
| Apr 29, 2026 | −$0.30 est −$0.77 | $246.0M est $195.6M | +4.2% |
| Feb 25, 2026 | −$1.41 est −$1.24 | $203.0M est $156.1M | −5.7% |
| Oct 29, 2025 | −$0.61 est −$1.15 | $156.7M est $153.6M | +0.8% |
| Jul 30, 2025 | $0.86 est $0.27 | $452.0M est $131.7M | +3.6% |
| Apr 30, 2025 | −$0.93 est −$1.13 | $131.6M est $150.6M | +6.4% |
| Feb 19, 2025 | −$0.43 est −$0.84 | $226.6M est $131.1M | +2.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Ionis Pharmaceuticals is $69.13, +137.9% from the last close, from 19 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 19 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 10 | Wells Fargo | $80 | +175.3% |
| Nov 10 | TD Cowen | $53 | +82.4% |
| Nov 10 | Oppenheimer | $70 | +140.9% |
| Nov 10 | H.C. Wainwright | $70 | +140.9% |
| Nov 10 | Goldman Sachs | $41 | +41.1% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Ionis Pharmaceuticals averaged −2.3% across the last 5 years, rising in 1 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.1% | 1 of 5 |
| Next 10 trading days | −4.2% | 2 of 5 |
| Next 15 trading days | −1.5% | 2 of 5 |
| Next 20 trading days | −2.3% | 1 of 5 |
| Next 30 trading days | −2.8% | 2 of 5 |
For scale, IONS’s typical 20-trading-day move in either direction is about 6.2%.
Ionis Pharmaceuticals’s market cap is $4.84B and revenue of $960.1M over the last twelve months.
Coverage of Ionis Pharmaceuticals this week reads negative: 4 positive, 2 neutral and 7 negative headlines.
Ionis Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
Ionis Pharmaceuticals’s market cap is $4.84B at the Nov 13, 2026 close of $29.06, with 166.5M shares outstanding.
The consensus analyst 12-month price target for Ionis Pharmaceuticals is $69.13, +137.9% from the last close. Of the 19 firms that rated the stock in the last 90 days, 18 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Ionis Pharmaceuticals is undervalued: the Nov 13, 2026 close of $29.06 is 44.5% below Gekko Fair Value of $52.36. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Ionis Pharmaceuticals is expected to report on Feb 24, 2027 (101 days away). Analysts expect earnings of −$1.35 per share on revenue of $178.9M. Ionis Pharmaceuticals beat the earnings estimate in 7 of its last 8 reports, moving 6.9% on average across the report.
Ionis Pharmaceuticals’s 52-week high is $86.74 and its 52-week low is $27.25; it closed at $29.06 on Nov 13, 2026, −60.0% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk) and 2 as headwinds (trend and seasonality). The checklist is a description of current data, not a recommendation.
Gekko flagged 2 unusual options signals in Ionis Pharmaceuticals over the last 30 days, with $334K of flagged premium in calls and $251K in puts. The latest, bearish flow, was on Oct 30, 2026 with $251K in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.